Skip to main content

Advertisement

SpringerLink
Log in

Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Annual MRI screening is recommended as an adjunct to mammography for BRCA1 and BRCA2 mutation carriers. Prophylactic oophorectomy has been shown to decrease breast cancer risk in BRCA1/2 mutation carriers. Here, we aimed to examine the combined effects of MRI and oophorectomy. For this purpose, 93 BRCA1/2 mutation carriers were screened with yearly mammograms and yearly MRI scans. Study endpoints were defined as date of breast cancer diagnosis, date of prophylactic mastectomy, or date of most recent contact. Of 93 women, with a median age of 47, 80 (86%) had prophylactic oophorectomy. Fifty-one women (55%) had BRCA1 mutations. A total of 283 MRI scans were performed. Eleven breast cancers (9 invasive, 2 ductal carcinoma in situ) were detected in 93 women (12%) with a median follow-up of 3.2 years (incidence 40 per 1,000 person-years). Six cancers were first detected on MRI, three were first detected by mammogram, and two were “interval cancers.” All breast cancers occurred in BRCA1 mutation carriers (incidence 67 per 1,000 person-years). Apart from BRCA1 vs. BRCA2 mutation status, there were no other significant predictors of breast cancer incidence. Most invasive breast cancers were estrogen receptor negative (7 of 9) and lymph node negative (7 of 9). There have been no systemic recurrences with a median follow-up of 19 months after cancer diagnosis. Finally, it was concluded that all breast cancers occurred in BRCA1 mutation carriers, in most cases despite oophorectomy. These data suggest that surveillance and prevention strategies may have different outcomes in BRCA1 and BRCA2 mutation carriers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130

    Article  CAS  PubMed  Google Scholar 

  2. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646

    Article  CAS  PubMed  Google Scholar 

  3. Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L et al (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18(19):3360–3369

    CAS  PubMed  Google Scholar 

  4. Domchek SM, Weber BL (2006) Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25(43):5825–5831

    Article  CAS  PubMed  Google Scholar 

  5. Robson M, Offit K (2007) Clinical practice. Management of an inherited predisposition to breast cancer [see comment]. N Engl J Med 357(2):154–162

    Article  CAS  PubMed  Google Scholar 

  6. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622

    Article  PubMed  Google Scholar 

  7. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609–1615

    Article  PubMed  Google Scholar 

  8. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296(2):185–192

    Article  CAS  PubMed  Google Scholar 

  9. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K et al (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23(30):7491–7496

    Article  PubMed  Google Scholar 

  10. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80–87

    Article  CAS  PubMed  Google Scholar 

  11. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7(3):223–229

    Article  CAS  PubMed  Google Scholar 

  12. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11(14):5175–5180

    Article  CAS  PubMed  Google Scholar 

  13. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH (2005) Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 23(34):8629–8635

    Article  PubMed  Google Scholar 

  14. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331–1337

    Article  PubMed  Google Scholar 

  15. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148(9):671–679

    PubMed  Google Scholar 

  16. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD et al (2007) American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89

    Article  PubMed  Google Scholar 

  17. Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A et al (2000) Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215(1):267–279

    CAS  PubMed  Google Scholar 

  18. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365(9473):1769–1778

    Article  CAS  PubMed  Google Scholar 

  19. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292(11):1317–1325

    Article  CAS  PubMed  Google Scholar 

  20. Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT et al (2007) Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 244(2):381–388

    Article  PubMed  Google Scholar 

  21. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437

    Article  CAS  PubMed  Google Scholar 

  22. Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X, Stoppa-Lyonnet D, Salmon R, for the IC-BOCRSG IC-BOCRSG: Institut Curie -Breast Ovary Cancer Risk Study Group (2007) Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer 109(9):1784–1790

    Article  CAS  PubMed  Google Scholar 

  23. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22(12):2328–2335

    Article  CAS  PubMed  Google Scholar 

  24. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91(17):1475–1479

    Article  CAS  PubMed  Google Scholar 

  25. Klaren HM, van’t Veer LJ, van Leeuwen FE, Rookus MA (2003) Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation [see comment]. J Natl Cancer Inst 95(13):941–947

    Article  PubMed  Google Scholar 

  26. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA 286(18):2251–2256

    Article  CAS  PubMed  Google Scholar 

  27. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary breast cancer clinical study group. Lancet 356(9245):1876–1881

    Article  CAS  PubMed  Google Scholar 

  28. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M et al (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118(9):2281–2284

    Article  CAS  PubMed  Google Scholar 

  29. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10(6):2029–2034

    Article  CAS  PubMed  Google Scholar 

  30. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318

    Article  CAS  PubMed  Google Scholar 

  31. Clarke RB, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57(22):4987–4991

    CAS  PubMed  Google Scholar 

  32. Zeps N, Bentel JM, Papadimitriou JM, D’Antuono MF, Dawkins HJ (1998) Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth. Differentiation 62(5):221–226

    Article  CAS  PubMed  Google Scholar 

  33. Evers B, Jonkers J (2006) Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 25(43):5885–5897

    Article  CAS  PubMed  Google Scholar 

  34. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19):1482–1485

    CAS  PubMed  Google Scholar 

  35. Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, Oudkerk M (2000) Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer 36(4):514–519

    Article  CAS  PubMed  Google Scholar 

  36. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE et al (2006) Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 295(20):2374–2384

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by the Cancer Genetics Network (HHSN21620074400C to SMD), the Marjorie Cohen Foundation (to SMD), the QVC Network-Fashion Footwear Association of New York (SMD), and NIH P01-CA-82707 (MS).

Author information

Authors and Affiliations

  1. Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    P. Shah, R. Kaltman, K. Armstrong, K. L. Nathanson & S. M. Domchek

  2. Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    M. Rosen & M. Schnall

  3. Abramson Cancer Center, University of Pennsylvania, 3 West Perelman Center, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA

    M. Rosen, J. Stopfer, R. Kaltman, K. Armstrong, K. L. Nathanson, M. Schnall & S. M. Domchek

  4. Pennsylvania Hospital, Philadelphia, PA, USA

    J. Siegfried & B. Mason

Authors
  1. P. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Stopfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Siegfried
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Kaltman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Mason
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Armstrong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. L. Nathanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Schnall
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. M. Domchek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. M. Domchek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shah, P., Rosen, M., Stopfer, J. et al. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Breast Cancer Res Treat 118, 539–546 (2009). https://doi.org/10.1007/s10549-009-0475-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0475-1

Keywords

Search

Navigation